泰林生物(300813) - 2022年1月5日投资者关系活动记录表

Group 1: Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. was listed on the Shenzhen Stock Exchange in January 2020, with stock code 300813 [1] - The company focuses on research and innovation in life sciences, medical engineering, and analytical instruments, providing systematic solutions for sterile production, toxicity control, quality assurance, precision medicine, and bio-safety [1][2] Group 2: Technological Innovation and Achievements - The company is recognized as a national high-tech enterprise and has established several research and development centers, holding 248 national patents and participating in over 20 national and industry standards [2] - During the pandemic, Tailin completed a directed procurement order for the second-phase expansion project of inactivated COVID-19 vaccine by China National Pharmaceutical Group, earning the title of "Quality Partner" [2] Group 3: Business Operations and Market Position - The main business includes the development, manufacturing, and sales of microbial detection and control technology systems, as well as organic analysis instruments, with applications in various fields such as healthcare, food safety, and environmental protection [2][3] - The company serves thousands of clients across pharmaceutical enterprises, food and drug inspection agencies, healthcare institutions, and research units [2] Group 4: Market Trends and Growth Potential - The global cell therapy technology market is projected to grow from $11.2 billion in 2017 to $34.41 billion by 2025, with a compound annual growth rate (CAGR) of 16.81% from 2018 to 2025 [3] - China's cell therapy market is expected to expand from 1.3 billion yuan in 2021 to 58.4 billion yuan by 2030, with an average annual growth rate of 53% [3] Group 5: Production Capabilities - The company has a complete production process including mold making, injection molding, sterilization, and assembly, with most structural components and core parts designed and manufactured in-house [4]